Vascular Biogenics Operating Income

Vascular Biogenics (VBLT) currently reports a operating income of $-64M as of June 2024. That compares with $-59M in the prior-year period — down 8.3% year over year. Use the charts on this page to explore Vascular Biogenics's operating income history and peer comparisons.

Vascular Biogenics's operating income decreased from $-59M to $-64M — a 8.3% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vascular Biogenics reported $-64M in operating income as of June 2024. That compares with $-59M in the prior-year period — down 8.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-64M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Vascular Biogenics, and consider following VBLT for alerts when major investors trade the stock.

Vascular Biogenics is classified in the Healthcare sector. On operating income, it currently shows $-64M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VBLT with unrelated industries.